Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase 1 Study

NCT02142530 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT02142530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02142530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase 1 Study
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2014
Completion date
January 31, 2018
Enrollment
19 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, non-hodgkin lymphoma, peripheral t-cell lymphoma